INSULET CORPORATION (NASDAQ:PODD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

21

INSULET CORPORATION (NASDAQ:PODD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02

Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
As described in Item 5.07 below, at the 2017 annual meeting of
stockholders (the 2017 Annual Meeting) of Insulet Corporation
(the Company) held on May 17, 2017, the Companys stockholders
approved the Companys 2017 Stock Option and Incentive Plan (the
2017 SOIP).
A detailed summary of the material terms of the 2017 SOIP
appear beginning on page 43 of the Companys definitive proxy
statement filed with the Securities and Exchange Commission on
April 7, 2017 (the Proxy Statement). The foregoing and the
description of the 2017 SOIP that appears in the Proxy
Statement are qualified in their entirety by reference to the
text of the 2017 SOIP, which is filed as Exhibit 10.1 hereto.
Item 5.07
Submission of Matters to a Vote of Security Holders
The Company held its 2017 Annual Meeting on May 17, 2017. For
more information on the following proposals, see the Proxy
Statement.
(a)
The stockholders elected each of the following three
nominees to the Board of Directors as Class I Directors,
each to serve for a three-year term and until his or her
successor has been duly elected and qualified or until his
or her earlier resignation or removal:
Nominee
Vote “For”
Vote “Withheld”
Broker Non-Votes
Sally Crawford
53,657,746
1,120,732
1,905,401
Regina Sommer
54,385,608
392,870
1,905,401
Joseph Zakrzewski
53,246,375
1,532,103
1,905,401
The terms in office of the Class II Directors (John A.
Fallon, M.D. and Timothy J. Scannell) and the Class III
Directors (Jessica Hopfield, Ph.D., David Lemoine and
Patrick J. Sullivan) continued after the 2017 Annual
Meeting.
(b)
The stockholders approved, on a non-binding, advisory
basis, the compensation of the Companys named executive
officers as disclosed in the Proxy Statement.
Vote “For”
Vote “Against”
Abstentions
Broker Non-Votes
49,542,709
4,886,376
349,393
1,905,401
(c)
The stockholders cast an advisory and non-binding vote on
whether future advisory and non-binding votes on executive
compensation should be held every one year, every two years
or every three years.
Every 1 Year
Every 2 Years
Every 3 Years
Abstentions
52,256,904
9,192
2,499,570
12,812
In accordance with these voting results, and consistent
with the recommendation of the Board of Directors, the
Company has determined that future advisory and
non-binding votes on executive compensation will be
held every year. Accordingly, the next advisory and
non-binding vote on executive compensation will be held
at the 2018 annual meeting of stockholders of the
Company.
(d)
The stockholders approved the 2017 SOIP.
Vote “For”
Vote “Against”
Abstentions
Broker Non-Votes
53,454,546
1,311,497
12,435
1,905,401
(e)
The stockholders ratified the appointment of Grant Thornton
LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31,
2017.
Vote “For”
Vote “Against”
Abstentions
Broker Non-Votes
56,620,637
57,817
5,425
No other matters were submitted for stockholder action.
Item 9.01 — Financial Statements and Exhibits
(d) Exhibits.
Exhibit
No.
Description
10.1
Insulet Corporation 2017 Stock Option and Incentive
Plan.


About INSULET CORPORATION (NASDAQ:PODD)

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.

INSULET CORPORATION (NASDAQ:PODD) Recent Trading Information

INSULET CORPORATION (NASDAQ:PODD) closed its last trading session up +0.81 at 42.00 with 349,107 shares trading hands.

An ad to help with our costs